Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its … Read more
Aclaris Therapeutics Inc (ACRS) - Net Assets
Latest net assets as of September 2025: $120.10 Million USD
Based on the latest financial reports, Aclaris Therapeutics Inc (ACRS) has net assets worth $120.10 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($175.53 Million) and total liabilities ($55.43 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $120.10 Million |
| % of Total Assets | 68.42% |
| Annual Growth Rate | N/A |
| 5-Year Change | 313.16% |
| 10-Year Change | 68.13% |
| Growth Volatility | 140.31 |
Aclaris Therapeutics Inc - Net Assets Trend (2013–2024)
This chart illustrates how Aclaris Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Aclaris Therapeutics Inc (2013–2024)
The table below shows the annual net assets of Aclaris Therapeutics Inc from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $155.55 Million | -1.03% |
| 2023-12-31 | $157.18 Million | -20.46% |
| 2022-12-31 | $197.62 Million | +0.14% |
| 2021-12-31 | $197.34 Million | +424.15% |
| 2020-12-31 | $37.65 Million | -46.15% |
| 2019-12-31 | $69.91 Million | -67.50% |
| 2018-12-31 | $215.12 Million | -4.50% |
| 2017-12-31 | $225.26 Million | +32.91% |
| 2016-12-31 | $169.49 Million | +83.19% |
| 2015-12-31 | $92.52 Million | +545.78% |
| 2014-12-31 | $-20.75 Million | -126.51% |
| 2013-12-31 | $-9.16 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aclaris Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 89369500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Comprehensive Income | $97.00K | 0.06% |
| Other Components | $1.06 Billion | 680.35% |
| Total Equity | $155.55 Million | 100.00% |
Aclaris Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Aclaris Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tianjin Saixiang Technology Co Ltd
SHE:002337
|
$318.26 Million |
|
Cerus Corporation
NASDAQ:CERS
|
$318.30 Million |
|
Xi'an High Voltage Apparatus Research Institute Co. Ltd.
SHG:688334
|
$318.33 Million |
|
Hyosung Advanced Materials Corp
KO:298050
|
$318.37 Million |
|
CIR S.p.A. - Compagnie Industriali Riunite
F:BN7
|
$318.19 Million |
|
Krispy Kreme Inc
NASDAQ:DNUT
|
$317.96 Million |
|
Beijing Strong Biotechnologies Inc
SHE:300406
|
$317.93 Million |
|
Jiangsu Rutong Petro-Machinery
SHG:603036
|
$317.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aclaris Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 157,179,000 to 155,554,000, a change of -1,625,000 (-1.0%).
- Net loss of 132,065,000 reduced equity.
- New share issuances of 74,913,000 increased equity.
- Other comprehensive income increased equity by 203,000.
- Other factors increased equity by 55,324,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-132.06 Million | -84.9% |
| Share Issuances | $74.91 Million | +48.16% |
| Other Comprehensive Income | $203.00K | +0.13% |
| Other Changes | $55.32 Million | +35.57% |
| Total Change | $- | -1.03% |
Book Value vs Market Value Analysis
This analysis compares Aclaris Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.93x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $-5.47 | $3.88 | x |
| 2014-12-31 | $-1.95 | $3.88 | x |
| 2015-12-31 | $4.97 | $3.88 | x |
| 2016-12-31 | $7.91 | $3.88 | x |
| 2017-12-31 | $8.02 | $3.88 | x |
| 2018-12-31 | $6.54 | $3.88 | x |
| 2019-12-31 | $1.69 | $3.88 | x |
| 2020-12-31 | $0.89 | $3.88 | x |
| 2021-12-31 | $3.48 | $3.88 | x |
| 2022-12-31 | $3.03 | $3.88 | x |
| 2023-12-31 | $2.25 | $3.88 | x |
| 2024-12-31 | $2.01 | $3.88 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aclaris Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -84.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -705.48%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 1.42x
- Recent ROE (-84.90%) is below the historical average (-61.72%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.32 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.44 Million |
| 2015 | -22.23% | 0.00% | 0.00x | 1.02x | $-29.82 Million |
| 2016 | -28.37% | 0.00% | 0.00x | 1.04x | $-65.03 Million |
| 2017 | -30.42% | -4071.48% | 0.01x | 1.08x | $-91.05 Million |
| 2018 | -61.70% | -1315.41% | 0.04x | 1.28x | $-154.25 Million |
| 2019 | -230.80% | -3817.22% | 0.04x | 1.41x | $-168.35 Million |
| 2020 | -135.87% | -789.17% | 0.09x | 1.88x | $-54.92 Million |
| 2021 | -46.04% | -1343.96% | 0.03x | 1.27x | $-110.60 Million |
| 2022 | -43.98% | -292.11% | 0.12x | 1.29x | $-106.67 Million |
| 2023 | -56.29% | -283.15% | 0.16x | 1.26x | $-104.20 Million |
| 2024 | -84.90% | -705.48% | 0.08x | 1.42x | $-147.62 Million |
Industry Comparison
This section compares Aclaris Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aclaris Therapeutics Inc (ACRS) | $120.10 Million | 0.00% | 0.46x | $318.20 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |